Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2009 June;21(2) > Minerva Biotecnologica 2009 June;21(2):111-21

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

  MOLECULAR IMAGING AND BIOTECHNOLOGY


Minerva Biotecnologica 2009 June;21(2):111-21

lingua: Inglese

MR “in vivo” preclinical molecular and cellular imaging

Geninatti-Crich S. 1, Lanzardo S. 2, Alberti D. 1, Aime S. 1

1 Department of Chemistry I.F.M and Center for Molecular Imaging (CIM) University of Turin, Turin, Italy
2 Department of Clinical and Biological Sciences Molecular Biotechnology Center University of Turin, Turin, Italy


FULL TEXT  


In respect to other molecular imaging modalities such as PET or SPECT, the low sensitivity is the main limitation of the Magnetic Resonance-Molecular Imaging (MRMI) approach. To overcome this limitation the imaging probe for MRMI applications must identify the target with high specificity and should provide sufficiently intense signal enhancement within the imaged volume to be easily distinguishable from un-enhanced tissue. Therefore, the success of a MRMI protocol strongly relies on the amplification effects associated to the accumulation of the agents at the cells of interest. A general route to get this goal consists of using nano-sized systems such as liposome, micelles, microemulsions, polymers etc… able to carry a huge payload of Gd complexes. A straightforward extension of this approach involves the use of naturally occurring nanosized aggregates such as apoferritin and lipoproteins (LDL, HDL). The nanocarriers are then functionalized with the suitable vectors that provide the overall particles with the required recognition capabilities towards the selected cellular target. MRI, with its high spatial resolution is also the technique of choice for the visualization of grafted cells (i.e. stem cells, pancreatic insule, T cells, etc.) in cell-based therapies. Examples of labeling strategies with MRI contrast agents are reported.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail